
Drugs in Pregnancy — Timing, Teratogens & Safe Prescribing
Every pregnancy carries a 2 to 3% background risk of a major malformation; drugs add to this only above a threshold dose and at the right time [1][4]
The first 2 weeks after conception are “all or none”; organogenesis (days 18 to 60) is the most sensitive time [1]
A few drugs are strong teratogens: valproate (about 10% malformations, 30 to 40% neurodevelopmental disorders), isotretinoin (about 25%) [3][4]
The FDA letter categories (A, B, C, D, X) were removed from 2015; labels now give a narrative risk summary [2]
Untreated illness also harms the baby; never stop essential medicines abruptly [1][3]
Avoid simple “safe or unsafe” lists; judge dose, route, timing and duration [1]
Principles: effect rises with dose; chronic exposure matters more than a single dose; skin products with little absorption rarely matter [1]
Thalidomide was a potent human teratogen missed in animal studies; animal data alone cannot prove safety [4]
| Drug | Effect and size of risk [4] | Safer choice [4] |
|---|---|---|
| Valproate | Malformations in about 10%; neurodevelopmental disorders in 30 to 40% [3]; spina bifida OR 12.7 | Lamotrigine or levetiracetam [3] |
| Carbamazepine, phenytoin, phenobarbital, topiramate | Raised malformation risk; dose-related for most [3] | Specialist choice; monotherapy |
| Isotretinoin | Structural defects about 25%; developmental delay a further 25% | Topical treatment; effective contraception |
| Warfarin | Embryopathy about 5%; higher above 5 mg a day | Heparin or enoxaparin |
| ACE inhibitors, ARBs | Kidney damage, oligohydramnios, lung hypoplasia (2nd and 3rd trimester) | Nifedipine, labetalol, methyldopa |
| Methotrexate | Miscarriage; multiple anomalies | Stop before conception (from memory) |
| Mycophenolate | Ear, lip, palate and heart defects | Specialist switch |
| Lithium | Ebstein anomaly; later studies show a smaller risk | Fetal echocardiography |
| Hydroxyurea (sickle cell disease) [5] | Untested in trials; studies of exposed pregnancies show low risk: in 178, no drug-related malformations, miscarriage 17%; long-term child outcomes unknown | Stop 3 months before planned conception (some advise 3 to 6) [5]; stop at once when pregnancy is diagnosed †; continue only case by case if high risk and transfusion is not possible [5] |
| Methimazole | Scalp defects, choanal or oesophageal atresia | PTU in the first trimester |
| Danazol, androgens | Virilisation of a female fetus | Avoid |
| Tetracyclines | Teeth and bone after the first trimester | Other antibiotics |
| Aminoglycosides (streptomycin, kanamycin) | Deafness with prolonged use | Short courses or alternatives |
| Fluconazole, high dose | Limb defects at 400 to 800 mg a day | Single 150 mg dose; topical |
| NSAIDs, late pregnancy | Ductus constriction, oligohydramnios | Paracetamol, up to 4 g a day |
| Paroxetine | Heart defects in two studies | Sertraline |
| Alcohol | Fetal alcohol syndrome in 6% of heavy drinkers’ babies | None is safe |
Use the drug with the most human pregnancy data, at the lowest effective dose, for the shortest time [3] (from memory)
One drug rather than several: malformation risk rose from 3% with one antiepileptic to 10% with three [1]
Folic acid 5 mg daily before conception for women on antiepileptics [3]; 4 to 5 mg for at least 3 months before conception [1]
Watch drug levels: lamotrigine and levetiracetam levels change in pregnancy and after birth [3]
Read the label narrative: Pregnancy, Lactation, and Females and Males of Reproductive Potential sections [2]
Report suspected adverse effects in mother or baby; enrol in pregnancy registries where available [2][3]
Use expert resources: teratology information services and LactMed for breastfeeding (from memory)
| Item | Detail [2] |
|---|---|
| Old system | Letter categories A, B, C, D, X; often misread as a risk grade |
| New system (PLLR) | In force from 30 June 2015; a narrative summary replaces the letter |
| Pregnancy section | Risk summary, clinical considerations (including dose changes), data, exposure registry |
| Lactation section | Drug in milk, effects on the breastfed baby |
| Reproductive potential | Pregnancy testing, contraception, fertility effects |
| Older drugs | Letters removed by 30 June 2018; over-the-counter labels unchanged |
Indian labels may still show letter categories; use them as a prompt to look further, not as a verdict (from memory)
Take a full history: dose, route, duration, gestation at exposure, reason, other exposures [1]
Give her the real numbers: compare with the 2 to 3% background risk [4]
Most exposures carry no measurable added risk; say so clearly (from memory)
Offer a detailed anomaly scan at 18 to 22 weeks when a structural risk exists; it cannot exclude every anomaly [1]
Refer complex cases to clinicians trained in clinical teratology [1]
Never advise termination on a drug exposure alone without expert counselling (from memory)
Stopping an antiepileptic or antidepressant abruptly on learning of pregnancy [1][3]
Valproate in a young woman with no contraception plan [3]
Relying on letter categories [2]
Forgetting over-the-counter, herbal and recreational products [1]
NSAIDs for pain late in pregnancy [4]
No folic acid for women on antiepileptics [1][3]
Frightening the woman with “unsafe” labels instead of numbers [1]
SAFER
| Abbreviation | Meaning |
|---|---|
| ACE | Angiotensin-converting enzyme |
| AED | Antiepileptic drug |
| ARB | Angiotensin receptor blocker |
| FDA | US Food and Drug Administration |
| MHRA | UK Medicines and Healthcare products Regulatory Agency |
| NSAID | Non-steroidal anti-inflammatory drug |
| OR | Odds ratio |
| PLLR | FDA Pregnancy and Lactation Labeling Rule |
| PTU | Propylthiouracil |
| LactMed | US National Library of Medicine drugs and lactation database |
[1] Polifka JE, Friedman JM. Medical genetics: 1. Clinical teratology in the age of genomics. CMAJ 2002;167(3):265-273.
[2] Whyte J. FDA implements new labeling for medications used during pregnancy and lactation. Am Fam Physician 2016;94(1):12-13.
[3] Medicines and Healthcare products Regulatory Agency. Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review. Drug Safety Update 2021;14(6), 7 January 2021.
[4] Weber RJ, Jauniaux ERM. Drugs and environmental agents in pregnancy and lactation: teratology, epidemiology, and patient management. Chapter 7 in a 2023 Elsevier obstetrics textbook (excerpt; believed to be Gabbe’s Obstetrics, 8th edition).
[5] Habibi A, et al. Study of pregnancies exposed to hydroxyurea in women with sickle cell disease (European prospective cohorts, 2009 to 2025; exact title not seen). Presented at the 67th American Society of Hematology Annual Meeting, 7 December 2025. (Read through the ASH news release; not yet peer-reviewed.)


